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SUMMARY
The possibility of detecting acute infection and immunity using body fluids that are easier to collect than blood, mainly in
children, would facilitate the investigation and follow-up of outbreaks of hepatitis A (HAV). Our study was carried out to evaluate the
detection of anti-HAV IgM, IgA and total antibodies in saliva using serum samples as reference. Forty three paired serum and saliva
samples were analyzed. From this total, 24 samples were obtained from children and 1 from one adult during the course of acute
hepatitis A; an additional 18 samples were obtained from health professionals from Adolfo Lutz Institute. The sensitivity to detect
anti-HAV IgM was 100% (95%CI: 79.1 to 100.0%), employing saliva as clinical samples. In detecting anti-HAV IgA, the sensitivity
was 80.8% (95%CI: 60.0 to 92.7%) and for the total antibodies was 82.1% (95%CI: 62.4 to 93.2%). The specificity was 100% for
each. The rate of agreement was high comparing the results of serum and saliva samples for detecting HAV antibodies. We conclude
that saliva is an acceptable alternative specimen for diagnosing acute hepatitis A infection, and for screening individuals to receive
hepatitis A vaccine or immunoglobulin.
KEYWORDS: Hepatitis A; Saliva; Antibodies; Vaccine
INTRODUCTION
Hepatitis A is one of the most common causes of infectious hepatitis
in the World and the major means of transmission include contamination
of water supply and food. It is caused by a virus that belongs to the
Picornaviridae family, genus Hepatovirus, HAV (HOLLINGER &
TICEHURST, 1996; KOFF, 1998).
Brazil is a country with a suboptimal network of public sanitation.
The prevalence of anti-HAV IgG antibody is high, reaching about 90%
of children by ten years of age (CARRILHO & SILVA, 1995). This
epidemiological profile could be changing, at least in certain social
groups, according to PINHO et al. (1998), who carried out a
seroepidemiological study on universitary students from a high social-
economic level, and found within that population only 19.6% were anti-
HAV positive. Clinically, hepatitis A follows an anicteric or completely
asymptomatic course in 95% of children, up to five years of age (ROSS
et al., 1991). In adults the disease is more severe and prolonged
(LEDNAR et al., 1985; ZACHOVAL & DEINHARDT, 1998), but does
not lead to a chronic carrier state (BATTEGAY et al., 1995).
An initial serological response against HAV is directly related to the
humoral immunity, given the formation of IgM, IgG and IgA antibodies,
which are detectable at the onset of symptoms (ROSS et al., 1991;
LEMON, 1985).
The anti-HAV IgM antibody is transient, generally persisting for six
to eight months after the acute infection. Its detection is therefore
indicative of recent infection by HAV (KOFF, 1992; LEMON &
STAPLETON, 1998; LOCARNINI et al., 1979).
The anti-HAV IgG antibody increases gradually, reaching high levels
during the convalescent phase (STAPLETON et al., 1991) and remains
for life, conferring immunity against reinfection.
Secretory IgA is associated with intestinal resistance to many viral
infections, as is the case of the Polioviruses. The oral vaccine, obtained
from attenuated viral strains, induces the production of this antibody
and protects against enteric reinfection. In spite of this, some authors
have shown that in case of infection by HAV, intestinal immunity does
not represent protection against this virus (STAPLETON, 1995).
Laboratory diagnosis in cases of Hepatitis A is established by
measuring in the serum the levels of intracellular hepatic enzymes (ALT
and AST) as well as by the detection of anti-HAV IgM antibodies in
blood samples (HESS et al., 1995).
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The difficulty in collecting blood samples, mainly in children, and
the ease and reliability of the collection of saliva samples have led various
authors to develop methods, or adapt already existing techniques, for
the detection of specific antibodies found in saliva (PARRY et al., 1987)
and in urine (PARRY, 1993).
During outbreaks of Hepatitis A, collection of blood samples is
usually necessary for serological testing and establishment of etiological
diagnosis. This diagnosis allows the determination of measures for
prevention and control of the disease. The general acceptance of collecting
saliva samples is far greater in the entire community and this would
greatly facilitate investigations and follow-up of outbreaks (PARRY,
1993). Saliva samples are less expensive to collect when compared to
blood samples.
The detection of antibodies in saliva was initially demonstrated by
ARCHIBALD et al. (1986). Since then, various studies were undertaken,
utilizing saliva samples not only for the diagnosis of recent and past
infection, but for evaluation of the response of the Hepatitis A vaccine
(LAUFER et al., 1995; OCHNUI et al., 1997; PARRY et al., 1987;
PARRY et al., 1989; PARRY, 1993; PIACENTINI et al., 1993; THIEME
et al., 1992).
The advantage of utilizing saliva in tests for the diagnosis of Hepatitis
A is the ease of collection, making this a satisfactory and convenient
alternative (PARRY et al., 1989), especially if we consider that in this
epidemiological setting the majority of the patients are children.
In the present study, we compared results obtained by the detection
of antibodies of the IgM, IgA and IgG class against HAV, in both saliva
and serum samples. We evaluated the possibility of replacing serum by
saliva samples for diagnosis and for selection of candidates for
vaccination against Hepatitis A.
MATERIAL AND METHODS
Fourty-three paired serum and saliva samples were analyzed. Twenty-
four of them were obtained from children involved in an outbreak of
hepatitis A which occurred in the country of São Sebastião da Grama,
São Paulo State, Brazil. One set of samples came from an adult with
acute hepatitis A and 18 other set of samples were provided by employees
from the Instituto Adolfo Lutz, apparently healthy and without clinical
or epidemiological risks of hepatitis.
Blood samples were subjected to centrifugation and serum was
separated and transferred to previously labelled 5 mL test tubes. Saliva
samples were obtained by utilizing Omni-SAL saliva collectors (Saliva
Diagnostic Systems, Singapore) and refrigerated at –20 oC until the
moment of testing. They were tested diluted 1:5, in phosphate buffered
saline (pH 7.4) with 1% bovine serum albumine (PBS-A). Serum samples
and the results obtained with them were used as reference samples, while
the saliva samples were utilized as alternatives.
The presence of anti-HAV antibodies of IgG, IgM and IgA classes
were assayed in both serum and saliva samples. In saliva samples, IgG
as well as IgM antibodies were detected by adaptations of commercial
enzyme immunoassays (SORIN® ETI-AB-HAVK-2, ETI-AB-HAVK-3
and ETI-HA-IgMK-2). Serum samples were substituted by saliva in the
first incubation period. The tests on serum were performed according to
the instructions of the producer.
For the experiments to detect IgA class antibody, the samples were
analyzed using SORIN® ETI-AB-HAVK-3 kits, with some modifications.
According to the procedures described by CROWTHER (1995),
polystyrene microplates were coated with 100µL of the goat anti-human
IgA antibody (SIGMA), diluted at 1:800 in 50 mM carbonate-bicarbonate
buffer (pH 9.6). After a 16 hours incubation, blocking was achieved
with 100µL of PBS-A. One hundred microliters of dilution of saliva
samples in PBS-A 1:5 was added and incubated at 4 oC for 18 to 20
hours. After this period, the microplate was washed four times with a
PBS/Tween (0.5 %) solution and 100µL of HAV antigen provided by
the commercial kit were added, and incubated at 37 oC for 2 hours.
Following this incubation and after washing the microplate wells, 100µL
conjugate were added (human antibody anti-HAV conjugated with
peroxidase, a reagent included in the SORIN-ETI-AB-HAVK-3 kit).
The final step of the reaction was the addition to each well of 100µL of
a substrate solution containing tetrametilbenzidine and hydrogen
peroxide buffered citrate. The microplate was incubated at room
temperature for 30 minutes, protected from light, and the reaction was
later interrupted by the addition of 100µL of sulfuric acid (1N) to each
well. The reading of the reaction was done using a microplate
spectrophotometer (Microwell System Reader 510 - Organon Teknika,
filter 492nm and 600nm) and the cut-off of the reaction was determined
by calculating the mean optical density (OD) of four known negative
samples and adding three standard deviations. Samples which showed
an OD above the cut-off value were considered positive.
Positive and negative controls were included in all experiments.
In order to assess the statistical significance of the association, 95%
confidence intervals (CI) were used.
RESULTS
Detection of total anti-HAV in saliva samples. Of the 43 paired
serum and saliva samples 28 were collected from serologically positive
subjects. A positive result was observed in 23/28, oral fluid specimens,
showing a sensitivity of 82.1% (95%CI: 62.4 to 93.2%); 15 subjects
were negative for serum as well as saliva, resulting in a specificity of
100% (95%CI: 74.7 to 100.0%). The agreement between the results of
the two clinical samples was 88.4%.
Detection of anti-HAV antibodies of the IgA class in saliva
samples. Of the 43 subjects 26 had detectable IgA anti-HAV in their
serum, of which 21 were also positive for this marker in saliva,
representing a sensitivity of 80.8% (95%CI: 60.0 to 92.7%) in both
clinical samples. Seventeen matched serum and saliva samples were
negative for this marker, resulting in a specificity of 100% (95%CI: 77.1
to 100.0%). The agreement between the results was 88.4 %.
Detection of anti-HAV antibodies of the IgM class in saliva
samples. Of the 43 matched sample sets analyzed, 19 were positive for
IgM antibodies while 24 were negative for this marker. We observed
complete agreement for the detection of the anti-HAV of the IgM class,
utilizing the same methodology but different clinical samples (serum
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and saliva), representing a sensitivitiy of 100.0% (95%CI: 79.1 to
100.0%) and specificity of 100.0% (95%CI: 82.8 to 100.0%).
DISCUSSION
Hepatitis caused by HAV can not be differentiated from other
etiologies, based only upon the clinical and epidemiologic characteristics.
The serum test for the detection of anti-HAV IgM is necessary to confirm
the etiologic diagnosis of the acute infection, while the detection of IgG
antibodies indicates immunity and long-lasting protection against the
virus. In the epidemiological setting found in Brazil, the finding of IgG
anti-HAV rarely can be used to clarify the diagnosis. For routine
laboratory diagnosis of acute Hepatitis A, commercially available
immunoenzymatic tests were used, employing sera as clinical samples.
Similarly our results demonstrate that saliva can be utilized in tests
for the detection of total antibodies against HAV, and that this strategy
could be applicable to screening vaccine candidates or candidates for
gammaglobulin injections, with a reasonable degree of confidence, as
we obtained a sensitivity of 82.1% and a specificity of 100% for this
marker.
STAPLETON (1995) and STAPLETON et al. (1991) have
demonstrated, by means of radioimmunoassay, the presence of anti-HAV
IgA, in 9 out of 14 saliva samples obtained from individuals during an
outbreak of Hepatitis A, 56 days after the onset of jaundice.
The detection of anti-HAV IgA in saliva and serum samples in our
study presented a sensitivity of 80.8% and a specificity of 100%.
Furthermore, an agreement of 88.4% between both types of samples,
serum and saliva, was obtained. We observed that anti-HAV IgA
antibodies in saliva and serum are slightly less detectable than the anti-
HAV IgG (21 and 23 out of 43 versus 23 and 26 out of 43).
LAUFER et al. (1995) analyzed the presence of IgG in saliva in
vaccinated individuals as well as in non-vaccinated people. They observed
100% of agreement in the detection of IgG acquired after natural
infection, while concordance among the vaccinated individuals was only
28%. This fact can be explained by the difference in the levels of
antibodies which were naturally produced as opposed to the ones acquired
by active immunization. In our study, we do not evaluate the response to
vaccination against Hepatitis A.
In relation to the detection of IgM, PARRY (1993) and PARRY et
al. (1987, 1989) using the competition radioimmunoassay, demonstrated
that anti-HAV IgM can be reliably detected in the saliva of patients with
acute or recently acquired Hepatitis A. Fourteen serum and saliva samples
with recent hepatitis, collected simultaneously, were tested for anti-HAV
IgM. Eight cases were confirmed as acute Hepatitis A by serum
examination. The reactivity in serum was very similar to the one found
in saliva. These authors observed that anti-HAV IgM in saliva samples
can be detected, in moderate levels, from two to four months after the
onset of symptoms. After this period, detection became practically
impossible.
Similarly, PIACENTINI et al. (1993), obtained a sensitivity of 100%
and a specificity of 98% in anti-HAV IgM detection tests in paired serum
and saliva samples.
In our study, anti-HAV IgM was detected in 19 simultaneously
collected serum and saliva samples, showing a concordance of 100%.
Altogether these data suggest the possibility of substitution of serum
by saliva as clinical samples for the diagnosis of acute Hepatitis A.
BULL et al. (1989), studying an outbreak of Hepatitis A in a school,
utilized saliva samples to carry out an epidemiologic investigation. Two
samples were collected from the entire school community at an interval
of ten weeks. In four individuals with acute Hepatitis A anti-HAV IgM
was detected. It persisted in the saliva for two to three months after
initiation of the clinical signs (jaundice), confirming the results that
PARRY et al. (1989) carried out at the same time.
THIEME et al. (1992) addressed the issue of the longevity of
antibody detection. The detection of anti-HAV IgM in saliva and serum
samples showed 100% sensitivity and 98% specificity. In the longitudinal
study of HAV in 5 patients, the IgM antibody decline in saliva and serum
samples was similar for both, though two patients showed a decline in
saliva samples before they did in serum samples. This decline could
have occurred due to the low sensitivity of the saliva test in relation to
the serum test or to the degradation of the antibodies by the salivary
enzymes. Anti-HAV IgM was detected in the saliva for 60 days and the
total anti-HAV (IgM and IgG) was detected for more than 320 days after
the onset of symptoms. The authors demonstrated that saliva can be
utilized as clinical samples for the diagnosis of acute infection and
monitoring of immunization against HAV.
Our study demonstrates and confirms the possibility of substitution
of serum by saliva in laboratory diagnosis of hepatitis A and in the
selection of individual candidates for active or passive immunization.
RESUMO
Detecção de anticorpos anti-VHA em amostras de saliva
utilizando teste imuno-enzimático
A possibilidade de identificar infecções presentes ou passadas
utilizando fluidos corpóreos que seriam mais facilmente coletados do
que o sangue, principalmente em crianças, facilitaria grandemente a
investigação e o acompanhamento de surtos de hepatite A, que ocorrem
com muita freqüência em nosso meio.
Nosso estudo foi desenvolvido com a finalidade de avaliar a detecção
dos anticorpos anti-VHA, da classe IgA, IgM, e anticorpos totais em
amostras de saliva, usando amostras de soro como padrão.
Foram estudadas 43 amostras pareadas de saliva e de soro, colhidas
de 24 crianças e de um adulto durante um surto de hepatite A, e de 18
funcionários do Instituto Adolfo Lutz.
Empregando saliva como amostra clínica, a sensibilidade para a
detecção de anti-VHA IgM foi de 100,0%, de anti-VHA IgA foi de
80,8% e de anti-VHA total foi de 82,1%. Não houve nenhum resultado
falso-positivo, sendo a especificidade de 100%.
A concordância foi alta entre os resultados das amostras de saliva e
soro na detecção dos anticorpos, indicando que amostras de saliva podem
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ser utilizadas no diagnóstico de infecção aguda pelo VHA e na seleção
de indivíduos para vacinação contra o VHA, para conter surtos.
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